TLOG — Tetralogic Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Cellect: Soars on merger deal with Quoin Pharmaceuticals
Brief: Tetralogic announces pacts to restructure convertible debt
Brief: Tetralogic Pharmaceuticals says Pete Meyers resigned as CFO
Brief: TetraLogic Pharmaceuticals says birinapant shows no activity in randomized phase 2 mds study
Brief: TetraLogic Q3 loss per share $0.46
Brief: TetraLogic Pharma says has an open U.S. IND application in support of phase 2 clinical trial of suberohydroxamic acid phenyl ester
Brief: TetraLogic Pharmaceuticals entered into purchase agreement with Lincoln Park Capital
Brief: TetraLogic Qtrly net loss per common share $0.42
Brief: TetraLogic says expects to start hep B trial in India by early 2016
Brief: TetraLogic announces update on MDS clinical program
Brief: TetraLogic terminates public offering
Brief: TetraLogic prices $25 million public offering
Brief: TetraLogic announces publication of two papers describing birinapant's preclinical activity in chronic hepatitis B
Brief: TetraLogic and Merck to evaluate birinapant Keytruda combination in solid tumors
Brief: TetraLogic and Merck enteres into oncology clinical study collaboration
Brief: TetraLogic Pharmaceuticals entered into sales agreement with Guggenheim Securities
Brief: TetraLogic qtrly loss per share $0.53
Brief: TetraLogic Pharmaceuticals files for mixed shelf of up to $150 million
Brief: TetraLogic to proceed with expansion phase of study in patients with ovarian cancer